Cargando…
Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150891/ https://www.ncbi.nlm.nih.gov/pubmed/36921117 http://dx.doi.org/10.1097/CM9.0000000000002453 |
| _version_ | 1785035434805428224 |
|---|---|
| author | Mao, Shiqi Luo, Libo Yang, Shuo Wang, Yan Zhou, Fei Yu, Jia Chen, Bin Gao, Guanghui Li, Xuefei Zhao, Chao Cheng, Lei Liu, Yiwei Wang, Wanying Jia, Keyi Shao, Chuchu Liu, Xinyu Chen, Xiaoxia Su, Chunxia Zhou, Caicun Wu, Fengying Ren, Shengxiang |
| author_facet | Mao, Shiqi Luo, Libo Yang, Shuo Wang, Yan Zhou, Fei Yu, Jia Chen, Bin Gao, Guanghui Li, Xuefei Zhao, Chao Cheng, Lei Liu, Yiwei Wang, Wanying Jia, Keyi Shao, Chuchu Liu, Xinyu Chen, Xiaoxia Su, Chunxia Zhou, Caicun Wu, Fengying Ren, Shengxiang |
| author_sort | Mao, Shiqi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10150891 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101508912023-05-02 Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation Mao, Shiqi Luo, Libo Yang, Shuo Wang, Yan Zhou, Fei Yu, Jia Chen, Bin Gao, Guanghui Li, Xuefei Zhao, Chao Cheng, Lei Liu, Yiwei Wang, Wanying Jia, Keyi Shao, Chuchu Liu, Xinyu Chen, Xiaoxia Su, Chunxia Zhou, Caicun Wu, Fengying Ren, Shengxiang Chin Med J (Engl) Correspondence Lippincott Williams & Wilkins 2023-04-05 2023-03-14 /pmc/articles/PMC10150891/ /pubmed/36921117 http://dx.doi.org/10.1097/CM9.0000000000002453 Text en Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
| spellingShingle | Correspondence Mao, Shiqi Luo, Libo Yang, Shuo Wang, Yan Zhou, Fei Yu, Jia Chen, Bin Gao, Guanghui Li, Xuefei Zhao, Chao Cheng, Lei Liu, Yiwei Wang, Wanying Jia, Keyi Shao, Chuchu Liu, Xinyu Chen, Xiaoxia Su, Chunxia Zhou, Caicun Wu, Fengying Ren, Shengxiang Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_full | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_fullStr | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_full_unstemmed | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_short | Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation |
| title_sort | outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with her2 mutation |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150891/ https://www.ncbi.nlm.nih.gov/pubmed/36921117 http://dx.doi.org/10.1097/CM9.0000000000002453 |
| work_keys_str_mv | AT maoshiqi outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT luolibo outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT yangshuo outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT wangyan outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT zhoufei outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT yujia outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chenbin outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT gaoguanghui outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT lixuefei outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT zhaochao outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chenglei outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT liuyiwei outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT wangwanying outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT jiakeyi outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT shaochuchu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT liuxinyu outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT chenxiaoxia outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT suchunxia outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT zhoucaicun outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT wufengying outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation AT renshengxiang outcomecomparisonofpyrotinibwithcurrentstandardofcareinthesecondthirdlinesettinginadvancednonsmallcelllungcancerpatientswithher2mutation |